Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1994-06-17
1995-05-30
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514909, 552601, A61K 3156
Patent
active
054201217
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to an anti-obesity agent and more specifically to an anti-obesity agent comprising cholest-4-en-3-one (4-cholesten-3-one) as an effective component.
BACKGROUND ART
The obesity means such a body condition that adipose tissue (body fat) is systemically overaccumulated and results from an energy intake higher than the energy expenditure over a long period of time. The obesity is accompanied by the limitation in the physicalactivity and the application of an excess load to various internal organs and results in various associated diseases such as arteriosclerosis, cancers and diabetes mellitus to thus ruin the obese person's health.
Until now, there have been proposed a variety of medicinal-therapeutic methods for preventing obesity, but these methods must solve various difficulties in order to ensure a satisfactory effect. For instance, the drug therapy using hormones or excitometabolics suffers from a problem that the decomposition of body proteins are promoted simultaneously with the decomposition of body fats. Among the hormone, a certain androgenic hormone has been known to show anti-obesity effects through the stimulation of the myotropic action and hence the promotion of the consumption of reserve fats. Examples of such androgenic hormones include dehydroepiandrosterone and 3-keto-.DELTA..uparw.9-19-norsteroid (Japanese Un-examined Patent Publication No. Hei 02-275895). In addition, anorectics and digestive enzyme-inhibitors suffer from a problem of side-effects such as nervous sympton and diarrhea.
Accordingly, an object of the present invention is to provide an anti-obesity agent free of the foregoing disadvantages.
Another object of the present invention is to provide a medicinal composition effective for the prevention and treatment of obesity.
A still another object of the present invention is to provide a method for preventing obesity and treating patients suffering from obesity.
DISCLOSURE OF THE INVENTION
The inventor of this invention has found out that 4-cholesten-3-one has a fat accummulation-inhibitory effect and that obesity can be prevented and treated through the administration of this compound, and thus have completed the present invention.
According to an aspect of the present invention, there is provided an anti-obesity agent which comprises 4-cholesten-3-one as an effective component and which is effective for the prevention and treatment of obesity.
According to another aspect of the present invention, there is provided a medicinal composition which comprises 4-cholesten-3-one as an effective component and a pharmaceutically acceptable excipient and which is effective for the prevention and treatment of obesity.
According to a still another aspect of the present invention, there is provided a method for preventing obesity and for treating a patient suffering from obesity, characterized in that an effective amount of 4-cholesten-3-one is administered to a person.
The anti-obesity agent of the present invention is quite useful since it is substantially non-toxic.
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 shows time-course in the averaged body weight of CDF1 mice in each group.
FIG. 2 shows the relation between the monthly age and the survival rate of CDF1 mice in each group.
FIG. 3 shows the averaged weights of the organs, i.e., brain, lung, heart, liver, kidneys, spleen and testes (or ovaries) of CDF1 mice of 18-month-old in each group.
FIG. 4 shows the averaged weights of the organs, i.e., pituitary gland and adrenal gland of CDF1 mice of 18-month-old in each group.
FIG. 5 shows the averaged amount of fats present in abdominal adipose tissues of CDF1 mice of 18-month-old in each group.
FIG. 6 shows time-course in the averaged body weight of CDF1 mice in each group.
FIG. 7 shows the averaged values of serum lipids of CDF1 mice in each group .
BEST MODE FOR CARRYING OUT THE INVENTION
4-Cholesten-3-one may be chemically synthesized or may be produced starting from cholesterol as a substrate using cholesterol oxidase (cholesterol:oxig
REFERENCES:
patent: 4003794 (1977-01-01), Sugiura et al.
Criares T. J.
Henley III Raymond
Rikagaku Kenkyusho
LandOfFree
Use of 4-cholesten-3-one as an anti-obesity agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 4-cholesten-3-one as an anti-obesity agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 4-cholesten-3-one as an anti-obesity agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-361916